Molecular Diagnostics Center
view more >>
- About MEDx
- Technology Centers
- Services
-
Products
IHC-Based AssaysPCR-Based AssaysNGS-Based AssaysMore AssaysCustomized AssaysSolid Tumor - Pan-Solid Tumors - Lung Cancer - Stomach Cancer - Breast Cancer - Soft Tissue Sarcoma - Other Cancer Types
Solid TumorBlood CancerRUO ProductsIVD/CDx Products - Clinical Testing
- Quality Systems
- Events
- Contact Us
- 400+Pharmaceutical Partners
- 150+Biomarker Assays
- 300+Method Validations
- 40+CDx
Technology Centers
Comprehensive Translational Medicine
Services
CDO Enabling Drug R&D
Products
A Leader of Companion Diagnostics Total-Solution Providers
Clinical Testing
Patient Testing for Precision Medicine
-
Pan solid tumor
Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC). -
Hematologic Malignancy
Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
Quality Systems
State-of-Art Facilities & Global-standard Quality Systems
About MEDx
Translational Medicine
MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.
Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.
Events
- Happy Chinese New Year
- MEDx TMC | Happy Mid-Autumn Festival
- MEDx Invite You: Medlab Asia & Asia Health on July 10th-12th, 2024
-
We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take
- MEDx TMC | Happy Father’s Day！
- Dragon Boat Festival
- Welcome to visit the MEDx Booth at Medlab Middle East 2024
-
Time：5-8 February, 2024Address：Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored
- Meet MEDx at Medlab Middle East | Dubai 2024
- On series |PIK3CA gene mutation and targeted therapy
-
Introduction The study of cancer has been extended from single genes to macrogenes, and from sing
-
07 Jul 2025Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Testview more >>
07 Jul 2025Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Testview more >>
-
07 Jul 2025Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problemsview more >>
07 Jul 2025Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problemsview more >>
- Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test
-
A combination of Amgen’s monoclonal antibody bemarituzumab and chemotherapy improved overall surviv
- Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems
-
Pfizer has terminated a Phase II trial that was evaluating its investigational fusion protein maplir
- CAR T Guardrail Removal Earns FDA Favor with CGT Community
-
FDA leaders Marty Makary and Vinay Prasad have struck a tone of urgency when it comes to bringing in
- Aggressive blood cancer: A key protein could pave the way for targeted therapies
-
Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progre
- Role of tumor microenvironment in nasopharyngeal carcinoma progression uncovered
-
A study led by clinician-scientists and researchers at the National Cancer Centre Singapore (NCCS) h
- 80% of colorectal cancers resist immunotherapy—this DNA treatment could help
-
A University of Alberta research team has identified a DNA structure that activates the immune syste
- Gene mutation could be target for 'ultrapersonalized' therapies in colon cancer
-
Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that c
- Surviving breast cancer tied to lower Alzheimer's risk: Radiation therapy may offer short-term prote
-
Research led by Samsung Medical Center finds breast cancer survivors exhibit an 8% lower risk of Alz
Follow MEDx
